The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

This has outpaced the Medical sector's gain of 0.26% and the S&P 500's loss of 3.48% in that time. Market participants will be closely following the financial results of Eli Lilly in its upcoming ...

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their ...

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of ...

Eli Lilly is expanding the supply ... cover people living with obesity for medical care — this needs to change," Patrik Jonsson, president of Lilly Cardiometabolic Health, said in a statement.